Global top-tier biopharma · Three-platform activation
Orchestrating a Triple Platform Activation at Fortune 50 Scale
I was brought into a global biopharma transformation at a moment of real pressure.
A major business shift had exposed the cost and inflexibility of several highly customized legacy systems across regulatory, clinical, and quality. Those systems had become too expensive to sustain, but the functions they supported could not tolerate disruption.
At the same time, the company was integrating newly appointed senior leaders from a recent acquisition. Several of them had already used a modern life sciences platform successfully in prior roles. That mattered. It created a rare opening to replace aging infrastructure with a more integrated operating model, backed by executives who already believed in the solution.
The opportunity was ambitious: activate three mission-critical enterprise platforms across regulatory, clinical, and quality, in parallel, at global enterprise scale. There was no existing playbook for doing that.
The Challenge
This was not a routine software rollout. It was a high-stakes operating shift with financial, organizational, and execution risk all at once.
The company needed to reduce technology spend significantly while keeping core functions fully operational. Regulatory submissions could not slip. Clinical work could not stall. Quality processes had to remain intact and inspection-ready throughout.
The complexity was not just technical. This effort cut across Regulatory, Clinical, Quality, IT, Legal, and Finance, and it was happening in the middle of an active post-acquisition integration. Legacy leaders, newly arrived executives, and the external platform partner were all working from different assumptions, timelines, and constraints.
There was no proven model for sequencing or governing a three-platform activation of this size. What was needed was not just delivery management, but senior-level orchestration: aligning stakeholders, creating confidence, and moving a path forward that had never been done before at this scale.
What I Did
I treated the acquisition not as a complication, but as leverage.
The incoming leaders already trusted the platform from prior experience, so my job was not to resell the idea. It was to turn that existing trust into internal momentum, executive alignment, and a practical path to action.
I helped connect the company's shifting business priorities to the modernization effort so the platform move was seen not as a technology project, but as an operational response to a changed business reality.
From there, I worked across senior stakeholders to shape and advance a combined proposal covering all three platform activations. That meant aligning leadership around cost, sequencing, business rationale, change impact, and delivery expectations across functions that normally do not move in lockstep.
Because no playbook existed, I helped build the activation framework from scratch. I coordinated the transition across regulatory, clinical, and quality domains, managed expectations both internally and with the platform partner, and kept the organization focused on continuity while it moved off costly legacy systems.
A critical part of the work was stakeholder navigation. Newly arrived leaders became credible internal champions. More skeptical legacy stakeholders were brought along through peer credibility and business logic, not pressure. Budget decision-makers were shown a practical case for change. Delivery teams were kept aligned with what the organization could realistically absorb.
Outcomes
I helped lead the coordinated activation of three mission-critical enterprise platforms at global scale, an unusually complex move in a highly regulated environment.
The company transitioned away from costly legacy infrastructure without disrupting core operations. Regulatory work continued without interruption. Clinical programs stayed on track. Quality processes remained intact through the transition.
What could have become a destabilizing mix of budget pressure, leadership change, and post-acquisition complexity became the catalyst for modernization. The leadership transition created advocacy. The acquisition created urgency. The business pressure created focus. My role was to turn those forces into alignment and execution.
Once the new operating model was in motion and the plans were drafted, I shifted into transitioning execution and then exited through a clean handoff.